Psoriasis is a predominantly chronic skin disease which may also affect the joints. Biotest develops innovative therapeutic strategies with the objective of improving quality of life for psoriasis patients, which is usually severely limited. The focus is on the monoclonal antibody BT-061 with its completely new action mechanism. Psoriasis is a predominantly chronic skin disease which may also affect the joints. Biotest develops innovative therapeutic strategies with the objective of improving quality of life for psoriasis patients, which is usually severely limited. The focus is on the monoclonal antibody BT-061 with its completely new action mechanism.